Improving Adherence to Adjuvant Endocrine Therapy in Sub-Saharan Africa: Challenges and Innovative Nurse-Driven Solutions

Temidayo A. Fadelu*,1,2, Lori Buswell1, Benjamin O. Anderson3

1Center for Global Cancer Medicine, Dana-Farber Cancer Institute, Boston, MA, USA
2Harvard Medical School, Boston, MA, USA
3Departments of Surgery and Global Health-Medicine, University of Washington, Seattle, WA, USA

*Corresponding author: Temidayo Fadelu, MD, MPH, Dana-Farber Cancer Institute, 450 Brookline Avenue, MA-1B-17, Boston, MA 02215, USA. Tel: +1 617 632 6401; Email: temidayo_fadelu@dfci.harvard.edu

Epidemiologic studies from sub-Saharan Africa (SSA) indicate that most patients with breast cancer have tumors that express estrogen and/or progesterone receptors. Endocrine therapy is a cornerstone in the management of these patients, particularly for patients with non-metastatic cancers that are potentially curable. Adjuvant endocrine therapy (AET) remains one of the most effective interventions to prevent cancer recurrence and prolong survival. Seminal international meta-analyses conducted in 2005 showed a yearly reduction in breast cancer mortality of over 30% with 5-years of AET.1 And more recent international studies highlight that longer duration of AET, up to 10 years, provides even greater survival benefit for patients with more advanced disease.2,3 Commonly used AET options, such as tamoxifen and non-steroidal aromatase inhibitors, are administered orally on a daily schedule that makes them well-suited for low- and middle-income countries (LMICs) and other limited resource settings where access to health systems is constrained. Despite its proven efficacy, adherence to AET remains a significant challenge around the world and in SSA, with studies showing that less than 50% of patients complete intended duration of therapy.4

Recent reviews of global studies, but including none from SSA, have identified several factors that are associated with nonadherence to AET. These factors include personal demographic factors; side-effects and quality of life; knowledge, beliefs, and attitudes; socio-behavioral factors like self-efficacy (the belief in one’s own capacity to achieve a health goal through behavior modification); and structural health-system factors.5,6 A variety of strategies have been evaluated in high-resource settings to address these barriers to AET adherence.7,8 However, there are gaps in the literature regarding barriers and facilitators of AET adherence in SSA, and more importantly, there are no rigorous studies from the SSA region evaluating possible interventions to improve adherence.

The study by Getachew et al examines the use of a multipronged nurse-led intervention to improve adherence to endocrine therapy in Ethiopia.9 While the concept of oral medication adherence may appear simple, it encompasses multiple components (see Fig. 1). AET medication nonadherence may refer to delay or lack of initiation, early discontinuation, or poor implementation (interruptions of daily use).10 Early discontinuation and poor implementation of AET have been linked to poor outcomes, highlighting the need for innovative and effective solutions.11,12

The Getachew et al study involves a cluster randomization trial of 8 hospitals in Ethiopia with ready access to tamoxifen, 4 each in the control and intervention arms. A prior study in Ethiopia including 51 patients eligible for AET showed that 25 (49%) did not initiate AET; and of the 26 patients who initiated AET, one-year persistence rate was low at 52%, with only 35% showing good adherence implementation.13 To address this AET adherence gap, the current study developed a multipronged intervention where nurses were trained to deliver patient education, provide literacy materials, give counseling, make phone call reminders, and actively monitor medication refills of patients at the intervention hospitals. The investigators assessed the efficacy of the intervention on AET adherence implementation and persistence at 6 and 12 months. The outcome measures were medication possession ratio (MPR) of 80% or higher; compliance with daily use as determined by a simplified medication adherence scale (SMAQ) score of over 80% or higher; and rates of medication persistence (proportion of eligible patient remaining on therapy). Of the evaluable patients at 12 months, the authors show relatively higher rates of adherence by MPR at 90% and 79% in the intervention and control groups, respectively (P = .302). The rates of adherence implementation by SMAQ were lower, but statistically significantly different at 70% and 45% in the intervention and control groups, respectively (P = .036). AET persistence at 12 months was also markedly higher in the intervention group (91%) compared with the control group (78%).
The authors also explored the possible impact of patient and social demographic factors on AET adherence.

This study is an important contribution highlighting some critical aspects of maintaining AET adherence. First, measuring several components of adherence are crucial to obtain a comprehensive picture as well as to better tailor interventions. In addition, in many LMICs such as Ethiopia, where there are limited numbers of trained oncologists, empowering, training, and utilizing nurses can be a valuable way to extend oncology services and improve care delivery. Medication adherence, toxicity monitoring, and counseling are important care aspects that can be led by nurses. There are other emerging examples of how these task-shifting models can meaningfully improve care delivery in rural, resource limited settings. The study also highlights the importance of using a multi-pronged approach to improving medication adherence; studies on adherence in other disease have shown that isolated interventions tend to be less effective than multi-faceted and contextually driven solutions. Finally, the study is a good example of using a pragmatic trial approach—in this case cluster randomization—to examine the efficacy of embedding interventions within routine care practices that are suitable for application in LMICs.

While the results showing improvements in adherence in the intervention group are promising, there are some important study limitations and caveats that highlight the many challenges of conducting behavioral interventional studies in LMICs:

- The results report adherence at the 1-year mark, which is less than the currently recommended 5-10 year duration of AET therapy. Randomized trials of adjuvant tamoxifen taken for 1-year, 2-years, and 5-years, have demonstrated reduced breast cancer recurrence rates at 10 years by 21%, 29%, and 47%, which corresponds to proportional mortality reductions of 12%, 17%, and 26%.
- Thus, while 1-year of endocrine therapy reduces the rates of both recurrence and death, these benefits can be more than doubled by continuing treatment for a full 5-year course.
- Continued attrition and therapy discontinuation over the course of AET therapy is typical, and some interventions that have shown efficacy in short-term adherence trials have not translated to longer-term adherence. Further follow-up beyond one year is warranted.
- Some differences between the control and intervention groups and the hospitals through which they were treated may partly explain the higher adherence rates in the intervention group. These differences included stage distribution (71% having advanced disease in the control group vs 46% in the intervention group), differences in prior use of endocrine therapy (5% vs 18%);

Funding

TAF is supported by a 2021 Conquer Cancer Breast Cancer Research Foundation Career Development Award for Diversity, Inclusion and Breast Cancer Disparities in honor of Susan Hirschhorn and in memory of her mother, supported by Breast Cancer Research Foundation.

Any opinions, findings, and conclusions expressed in this material are those of the author(s) and do not necessarily reflect those
of the American Society of Clinical Oncology or Conquer Cancer, or Breast Cancer Research Foundation or any other funders.

**Conflict of Interest**
The authors indicated no financial relationships.

**Author Contributions**
Manuscript writing: All authors. Final approval of manuscript: All authors.

**References**

1. Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. *Lancet*. 2005;365(9472):1687-1717. https://doi.org/10.1016/S0140-6736(05)66544-0.

2. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. *Lancet*. 2011;378(9793):771-784. https://doi.org/10.1016/S0140-6736(11)60993-8.

3. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. *Lancet*. 2013;381(9869):805-816. https://doi.org/10.1016/S0140-6736(12)61963-1.

4. Hershman DL, Kushi LH, Shao T, et al. Early Discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. *Breast Cancer Res Treat*. 2011;126(2):529-537. https://doi.org/10.1007/s10549-010-1132-4.

5. Reibold CF, Tariku W, Eber-Schulze P, et al. Adherence to newly implemented tamoxifen therapy for breast cancer patients in Rural Western Ethiopia. *BRC*. 2021;16(5):484-490. https://doi.org/10.1159/000512840.

6. Challinor JM, Galassi AL, Al-Ruzzieh MA, et al. Nursing’s potential to address the growing cancer burden in low- and middle-income countries. *J Glob Oncol*. 2021;7(3):154-163. https://doi.org/10.1200/JGIO.2020.01974.

7. Shulman LN, Mpunga T, Tapela N, et al. Bringing cancer care to the poor: experiences from Rwanda. *Nat Rev Cancer*. 2014;14(12):815-821. https://doi.org/10.1038/nrc3848.

8. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. *The Lancet*. 1998;351(9114):1451-1467. https://doi.org/10.1016/S0140-6736(97)11423-4.

9. Montgomery AA, Peters TJ, Little P. Design, analysis and reporting of factorial randomised controlled trials. *BMC Med Res Methodol*. 2003;3(1):26. https://doi.org/10.1186/1471-2288-3-26.

10. Hemming K, Haines TP, Chilton PJ, Girling AJ, Lilford RJ. The stepped wedge cluster randomised trial: rationale, design, analysis, and reporting. *BMJ* 2015;350:h391. https://doi.org/10.1136/bmj.h391.

11. Erfani P, Bhangdia K, Stauber C, et al. Economic evaluations of breast cancer care in low- and middle-income countries: a scoping review. *Oncologist*. 2021;26(8):e1406–e1417. https://doi.org/10.1002/ongo.13841.

12. Galassi A, Challinor J. Strengthening the oncology nurse workforce in low-income and middle-income countries. *Lancet Oncol*. 2015;16(8):887-888. https://doi.org/10.1016/S1470-2045(15)00144-8.